PRAZIQUANTEL

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H24N2O2
Molecular Weight	312.4061
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C(C1CCCCC1)N2CC3N(CCC4=CC=CC=C34)C(=O)C2

InChI

InChIKey=FSVJFNAIGNNGKK-UHFFFAOYSA-N

InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB01058
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018714s013lbl.pdf https://en.wikipedia.org/wiki/Praziquantel

Praziquantel, marketed as Biltricide, is an anthelmintic used in humans and animals for the treatment of tapeworms and flukes. Specifically, it is effective against schistosoma, Clonorchis sinensis the fish tape worm Diphyllobothrium latum. Praziquantel works by causing severe spasms and paralysis of the worms' muscles. This paralysis is accompanied - and probably caused - by a rapid Ca 2+ influx inside the schistosome. Morphological alterations are another early effect of praziquantel. These morphological alterations are accompanied by an increased exposure of schistosome antigens at the parasite surface. The worms are then either completely destroyed in the intestine or passed in the stool. An interesting quirk of praziquantel is that it is relatively ineffective against juvenile schistosomes. While initially effective, effectiveness against schistosomes decreases until it reaches a minimum at 3-4 weeks. Effectiveness then increases again until it is once again fully effective at 6-7 weeks. Glutathione S-transferase (GST), an essential detoxification enzyme in parasitic helminths, is a major vaccine target and a drug target against schistosomiasis. Schistosome calcium ion channels are currently the only known target of praziquantel. The antibiotic rifampicin decreases plasma concentrations of praziquantel. Carbamazepine and phenytoin are reported to reduce the bioavailability of praziquantel. Chloroquine reduces the bioavailability of praziquantel. The drug cimetidine heightens praziquantel bioavailability.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-activated calcium channel beta 1 subunit 1 Target ID: CHEMBL2363079 Sources: http://www.drugbank.ca/drugs/DB01058	Blocker 555
Voltage-activated calcium channel beta 2 subunit 1 Target ID: CHEMBL2363080 Sources: http://www.drugbank.ca/drugs/DB01058	Blocker 555

Conditions

Condition	Modality	Highest Phase	Product
Schistosoma mekongi infection 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018714s013lbl.pdf	Curative	Approved 8583	BILTRICIDE Approved Use for the treatment of infections due to: all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium), and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated Launch Date 1984
Schistosoma japonicum infection 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018714s013lbl.pdf	Curative	Approved 8583	BILTRICIDE Approved Use for the treatment of infections due to: all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium), and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated Launch Date 1984
Schistosoma hematobium infection 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018714s013lbl.pdf	Curative	Approved 8583	BILTRICIDE Approved Use for the treatment of infections due to: all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium), and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated Launch Date 1984
Clonorchis sinensis/Opisthorchis viverrini 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018714s013lbl.pdf	Curative	Approved 8583	BILTRICIDE Approved Use for the treatment of infections due to: all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium), and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated Launch Date 1984

C_max

Value	Dose	Analyte	Population
0.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27152952/	25 mg/kg 3 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered:	PRAZIQUANTEL, (R)- plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27152952/	25 mg/kg 3 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered:	PRAZIQUANTEL, (S)- plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.83 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018714s018lbl.pdf	40 mg/kg single, oral dose: 40 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	PRAZIQUANTEL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
1.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27152952/	25 mg/kg 3 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered:	PRAZIQUANTEL, (R)- plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27152952/	25 mg/kg 3 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered:	PRAZIQUANTEL, (S)- plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.02 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018714s018lbl.pdf	40 mg/kg single, oral dose: 40 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	PRAZIQUANTEL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
1.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27152952/	25 mg/kg 3 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered:	PRAZIQUANTEL, (R)- plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27152952/	25 mg/kg 3 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered:	PRAZIQUANTEL, (S)- plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.99 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018714s018lbl.pdf	40 mg/kg single, oral dose: 40 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	PRAZIQUANTEL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
20% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27152952/	25 mg/kg 3 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered:		PRAZIQUANTEL, (S)- plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1800 mg single, oral Studied dose Dose: 1800 mg Route: oral Route: single Dose: 1800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/10991886	healthy, 26 - 47 Health Status: healthy Age Group: 26 - 47 Sources: https://pubmed.ncbi.nlm.nih.gov/10991886	Sources: https://pubmed.ncbi.nlm.nih.gov/10991886
100 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 100 mg/kg, 1 times / day Route: oral Route: multiple Dose: 100 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2209679	unhealthy, 32 ± 15 Health Status: unhealthy Age Group: 32 ± 15 Sources: https://pubmed.ncbi.nlm.nih.gov/2209679	Sources: https://pubmed.ncbi.nlm.nih.gov/2209679

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946		substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 879 P-gp 1741	CYP 303 CYP1A2 1197 CYP2C19 1119 CYP3A5 446 P-gp 2052	CYP1A1 151 CYP1A2 832

Drug as perpetrator

Target	Modality	Activity
CYP1A1 272	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/12451431/	no
CYP1A2 2333	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/12451431/	no
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27522191/	no
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/8896890/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27522191/; https://pubmed.ncbi.nlm.nih.gov/16846720/	no
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/32700798/	yes
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/32700798/	yes
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/32700798/	yes
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/32700798/	yes
CYP3A5 446	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/32700798/	yes
CYP 303	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018714s018lbl.pdf Page: 2, 3, 4, 5, 7	yes	yes (co-administration study) Comment: praziquantel AUC decreased 23% and Cmax y 35% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018714s018lbl.pdf Page: 2, 3, 4, 5, 7

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY560100	https://www.001chemical.com/chem/55268-74-1
001 Chemical	DY561296	https://www.001chemical.com/chem/57452-98-9
3B Scientific (Wuhan) Corp	3B1-00033	http://www.3bsc.com/index/pro_info.php?id=20245
3B Scientific (Wuhan) Corp	3B2-0731	http://www.3bsc.com/index/pro_info.php?id=20087
AA Blocks	AA0035RT	https://www.aablocks.com/goods/Goods/detail?id=AA0035RT
Aaron Chemicals	AR0036JL	http://www.aaronchem.com/55268-74-1
abcr GmbH	AB401012	http://www.abcr.com/shop/en/AB401012
AbMole Bioscience	M2162	http://www.abmole.com/products/praziquantel.html
Acadechem	ACDA-01001	http://acadechemical.com/product/229103
Accela ChemBio Inc	SY052322	http://www.accelachem.com/cn/search.html?keyword=SY052322&attname=GoodsCode
Achemica	ACMC-20emeg	http://www.achemica.com/prodinfo/?id=146477
Achemtek	0104-014690	http://www.achemtek.com/55268-74-1
Acorn PharmaTech	ACN-038368	http://www.acornpharmatech.com/
AHH Chemical co.,ltd	API-1703	http://www.ahhchemical.com/product/API-1703.html
AK Scientific, Inc. (AKSCI)	70292	http://www.aksci.com/item_detail.php?cat=70292
AK Scientific, Inc. (AKSCI)	J10194	http://www.aksci.com/item_detail.php?cat=J10194
Alfa Chemistry	AP1246343361	https://reagents.alfa-chemistry.com/product/praziquantel-cyclohexyl-d11-cas-1246343-36-1-3185.html
Alfa Chemistry	AP55268741-A	https://reagents.alfa-chemistry.com/product/praziquantel-cas-55268-74-1-13026.html
Alfa Chemistry	AP55268741-B	https://reagents.alfa-chemistry.com/product/praziquantel-cas-55268-74-1-13027.html
Ambinter	Amb1784750	http://www.ambinter.com/reference/1784750
Angene	AGN-PC-0SIX4N	http://www.angenechemical.com/productshow/AGN-PC-0SIX4N.html
Ark Pharm	AK161796	http://www.arkpharminc.com/products/55268-74-1.html
Aurora Fine Chemicals LLC	A13.143.162	http://online.aurorafinechemicals.com/info?ID=A13.143.162
Aurum Pharmatech LLC	NE56665	http://www.Aurumpharmatech.com/Product/ProductDetails/NE56665
Avantor Inc	TCP2125-25G	https://us.vwr.com/store/product/16814174/praziquantel-98-0-by-hplc-total-nitrogen
Avantor Inc	TCP2125-5G	https://us.vwr.com/store/product/16814174/praziquantel-98-0-by-hplc-total-nitrogen
BioChemPartner	BCP17829	http://www.biochempartner.com/57452-98-9-BCP17829
BioChemPartner	BCP28525	http://www.biochempartner.com/55268-74-1-BCP28525
BioChemPartner	BCP30228	http://www.biochempartner.com/57452-97-8-BCP30228
BioCrick	BCC4829	http://www.biocrick.com/Praziquantel-BCC4829.html
BioSynth	Q-201612	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/Q-201612.html
BLD Pharm	BD149008	http://www.bldpharm.com/products/55268-74-1.html
BOC Sciences	57452-97-8	https://www.bocsci.com/s-praziquantel-cas-57452-97-8-item-453193.html
BOC Sciences	57452-98-9	https://www.bocsci.com/r-praziquantel-cas-57452-98-9-item-483257.html
Chem Scene	CS-2223	http://www.chemscene.com/55268-74-1.html
Chemenu	CM110520	http://www.chemenu.com/products/CM110520
ChemMol	30101537	http://www.chemmol.com/chemmol/30101537.html
ChemMol	49402463	http://www.chemmol.com/chemmol/49402463.html
Chemspace	CSSB00000695716	https://chem-space.com/CSSB00000695716
Clearsynth	CS-T-40383	https://www.clearsynth.com/en/CST40383.html
Combi-Blocks	OR-5538	http://www.combi-blocks.com/cgi-bin/find.cgi?OR-5538
CSNpharm	CSN11763	https://www.csnpharm.com/products/praziquantel.html
DC Chemicals	DCAPI1247	http://www.dcchemicals.com//product_show-Praziquantel_Biltricide_.html
Debye Scientific	DB-052707	http://www.debyesci.com/cas_55268-74-1.html
Enamine	Z1563145961	https://www.enaminestore.com/catalog/Z1563145961
eNovation Chemicals	K35770	https://www.enovationchem.com/ProductDetails.asp?ProductID=K35770
Finetech	FT-0630676	http://www.finetechnology-ind.com/prod/detail/pub/55268-74-1.html
Glentham Life Sciences	GA8950	http://www.glentham.com/products/product/GA8950/
Hairui	HR125917	http://www.hairuichem.com/en/product/55268-74-1.html
iChemical	EBD43159	http://www.ichemical.com/products/55268-74-1.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN00192924	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00192924
mcule	MCULE-1638759858	https://mcule.com/MCULE-1638759858/
MedChem Express	HY-B0244	https://www.medchemexpress.com/Praziquantel.html
Molcore	MC560100	https://www.molcore.com/product/55268-74-1
Molcore	MC561296	https://www.molcore.com/product/57452-98-9
MuseChem	M109434	https://www.musechem.com/product/M109434.html
Oakwood	358136	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=195496&ExtHyperLink=1
OChem	4915	http://www.ocheminc.com/index.php?act=psearch&pid=268P741
Parchem	11055	http://www.parchem.com/chemical-supplier-distributor/Praziquantel-001055.aspx
Renno Tech	RP17849	http://www.rennotech.com/product_show.asp?id=23725
Sigma-Aldrich	1554603_USP	https://www.sigmaaldrich.com/catalog/product/usp/1554603?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	46648_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/46648?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	P2670000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/p2670000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	P4668_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/p4668?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	PHR1391_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/phr1391?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S540133	http://www.smolecule.com/products/s540133
Smolecule	S793333	https://www.smolecule.com/products/s793333
TCI (Tokyo Chemical Industry)	P2125	http://www.tcichemicals.com/eshop/en/us/commodity/P2125/index.html
THE BioTek	bt-279667	https://www.thebiotek.com/product/inhibitors/bt-279667
TripleBond	CP0098	http://www.triplebond-canada.com/prod/1527/
VladaChem	VL279771-1G	https://www.vladachem.com/product.php?products=55268-74-1
Yuhao Chemical	RT9840	http://www.chemyuhao.com/55268-74-1.html

PubMed

Title	Date	PubMed
Control of Echinococcus granulosus in Uruguay: evaluation of different treatment intervals for dogs.	2002-02-04	11777612
The effect of Nigella sativa oil against the liver damage induced by Schistosoma mansoni infection in mice.	2002-01	11744288
Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.	2001-12-19	11747748
Diphyllobothrium latum infection after eating domestic salmon flesh.	2001-12	11775333
Control of clonorchiasis by repeated treatments with praziquantel.	2001-12	11775328
Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites.	2001-12	11772354
Acidic vesicles of Schistosoma mansoni.	2001-12	11763428
The potential of artemether for the control of schistosomiasis.	2001-12	11730781
Isolation and identification of 8-hydroxypraziquantel as a metabolite of the antischistosomal drug praziquantel.	2001-12	11600290
Optimization of the single-day praziquantel therapy for neurocysticercosis.	2001-11-27	11723297
Development and validation of a 'tablet pole' for the administration of praziquantel in sub-Saharan Africa.	2001-11-15	11706670
Efficacy of praziquantel against Schistosoma japonicum: field evaluation in an area with repeated chemotherapy compared with a newly identified endemic focus in Hunan, China.	2001-11-15	11706669
Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study.	2001-11-15	11679932
[Tactics of wide use of praziquantel in the complex of measures for prevention of opisthorchiasis. 3. General approach for ambulatory treatment of patients with opisthorchiasis in disease reservoirs].	2001-11-13	11702451
Just another hemoptysis or a fluke?	2001-11	11732350
Urinary schistosomiasis in southern Ghana: a logistic regression approach to data from a community-based integrated control program.	2001-11	11716102
Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence.	2001-11	11703840
Impact of schistosomiasis on patient and graft outcome after renal transplantation: 10 years' follow-up.	2001-11	11682670
Prospects in medical management of Echinococcus granulosus.	2001-10-27	11677989
[Anemia, eosinophilia and generalized weakness in a 20-year old African].	2001-10-15	11715336
Human susceptibility to Schistosoma japonicum in China correlates with antibody isotypes to native antigens.	2001-10-03	11579893
[Subretinal granuloma, retinal vasculitis and keratouveitis with secondary open-angle glaucoma in schistosomiasis].	2001-10	11699321
A baseline study on the importance of bovines for human Schistosoma japonicum infection around Poyang Lake, China.	2001-10	11693868
Reinfection with Schistosoma haematobium following school-based chemotherapy with praziquantel in four highly endemic villages in Côte d'Ivoire.	2001-10	11679130
Acute colonic obstruction due to schistosomiasis in conjunction with ingestion of mangos.	2001-10	11676071
Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions.	2001-10	11532559
Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts.	2001-09-20	11565520
Tropical warts.	2001-09-08	11564489
Spinal-cord involvement in the hepato-splenic form of Schistosoma mansoni infection.	2001-09	11672470
Combined praziquantel and albendazole chemoprophylaxis in experimental hydatidosis.	2001-09	11570568
Susceptibility of Schistosoma japonicum to praziquantel in China.	2001-09	11555438
In vitro effects of isoprinosine and a dipeptide methyl ester on Echinococcus multilocularis protoscoleces.	2001-09	11551315
In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel.	2001-09	11513892
Counterfeit praziquantel.	2001-08-25	11545078
Depletion of praziquantel in plasma and muscle tissue of cultured rockfish Sebastes schlegeli after oral and bath treatment.	2001-08-02	11558729
Praziquantel--quality, dosages and markers of resistance.	2001-08	11685889
Pharmacokinetics and microsomal oxidation of praziquantel and its effects on the P450 system in three-month-old lambs infested by Fasciola hepatica.	2001-08	11555180
Acanthoparyphium tyosenense: the discovery of human infection and identification of its source.	2001-08	11534643
A rare case of eosinophilic pleuritis due to sparganosis.	2001-08	11518125
A comparative trial of albendazole alone versus combination of albendazole and praziquantel for treatment of Trichuris trichiura infection.	2001-06	11556579
Schistosoma mansoni and Biomphalaria: past history and future trends.	2001	11769285
[Schistosomiasis of the spinal cord. Case report].	2001	11706445
Primary hydatid cyst of the axillary region: report of a case.	2001	11686559
Replacing oxamniquine by praziquantel against Schistosoma mansoni infection in a rural community from the sugar-cane zone of Northeast Brazil: an epidemiological follow-up.	2001	11586444
The impact of repeated treatment with praziquantel of schistosomiasis in children under six years of age living in an endemic area for Schistosoma haematobium infection.	2001	11586443
T cell clones from Schistosoma haematobium infected and exposed individuals lacking distinct cytokine profiles for Th1/Th2 polarisation.	2001	11586432
Schistosomiasis epidemiology and control: how did we get here and where should we go?	2001	11586422
Voltammetric determination of praziquantel in tablets and biological fluids.	2001	11556129
Evaluation of efficacy of school-based anthelmintic treatments against anaemia in children in the United Republic of Tanzania.	2001	11545325
Optimising the benefits of anthelmintic treatment in children.	2001	11513281

Patents

Sample Use Guides

In Vivo Use Guide

For schistosomiasis: 20 mg/kg body weight three times a day as a one day treatment, at intervals of not less than 4 hours and not more than 6 hours.

Route of Administration: Oral

In Vitro Use Guide

To discern whether stage-specific resistance of Schistosoma mansoni to praziquantel occurs in vitro, was determined minimal effective concentrations (MECs) of drug needed to increase motor activity, produce contraction and/or paralysis, and cause tegumental vesiculation of developmental stages from day 0 to day 42 of S. mansoni. Recovery of these stages from exposure to praziquantel in vitro was also evaluated. MECs of praziquantel inducing increased motor activity and muscular contraction or paralysis or both were 0.005-0.01 ug/ml, irrespective of the stage examined.

Name

Type

Language

BILTRICIDE

Preferred Name

English

PRAZIQUANTEL

Official Name

English

PRAZIQUANTEL [VANDF]

Common Name

English

EMBAY-8440

Code

English

PRAZIQUANTEL [ORANGE BOOK]

Common Name

English

PRAZIQUANTEL [MI]

Common Name

English

PROFENDER COMPONENT PRAZIQUANTEL

Brand Name

English

PRAZIQUANTEL [USP-RS]

Common Name

English

Praziquantel [WHO-DD]

Common Name

English

PRAZIQUANTEL [MART.]

Common Name

English

BROADLINE COMPONENT PRAZIQUANTEL

Brand Name

English

PRAZIQUANTEL [USP IMPURITY]

Common Name

English

EMBAY 8440

Code

English

PRAZIQUANTEL (EMA EPAR: VETERINARY)

Common Name

English

PRAZIQUANTEL [EP MONOGRAPH]

Common Name

English

PRAZIQUANTEL [WHO-IP]

Common Name

English

CYSTICIDE

Brand Name

English

PRAZIQUANTEL [JAN]

Common Name

English

PRAZIQUANTEL [GREEN BOOK]

Common Name

English

2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

Common Name

English

PRAZIQUANTEL [USAN]

Common Name

English

PRAZIQUANTEL [USP MONOGRAPH]

Common Name

English

4H-PYRAZINO(2,1-A)ISOQUINOLIN-4-ONE, 2-(CYCLOHEXYLCARBONYL)-1,2,3,6,7,11B-HEXAHYDRO-

Common Name

English

NSC-757285

Code

English

PRAZIQUANTELUM [WHO-IP LATIN]

Common Name

English

praziquantel [INN]

Common Name

English

Classification Tree Code System Code

EMA VETERINARY ASSESSMENT REPORTS

PROFENDER [AUTHORIZED]